Information for healthcare professionals

NEW. Now available in Canada

Ozempic®. For adults with type 2 diabetes to improve glycemic control, when diet and exercise plus maximal tolerated metformin dose alone do not achieve adequate glycemic control.

SAFETY INFORMATION

Indications and clinical use:

Ozempic® is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with:

  • diet and exercise in patients for whom metformin is inappropriate due to contraindication or intolerance
  • metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control
  • metformin and a sulfonylurea, when diet and exercise plus dual therapy with metformin and a sulfonylurea do not achieve adequate glycemic control
  • basal insulin with metformin, when diet and exercise plus basal insulin with metformin do not achieve adequate glycemic control

Not a substitute for insulin. Not for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. Ozempic® is not indicated for use in pediatric patients.

Contraindications:

  • Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Pregnancy or breastfeeding

Most serious warnings and precautions:

Risk of thyroid C-cell tumours: In both genders of rats and mice, semaglutide causes treatment-dependent thyroid C-cell tumours. Patients should be counselled regarding the risk and symptoms of thyroid tumours.

Other relevant warnings and precautions:

  • Should not be administered intramuscularly
  • Pancreatitis
  • Hypoglycemia with concomitant use of insulin secretagogues or insulin
  • Use with other incretin drugs
  • Hypersensitivity
  • Diabetic retinopathy: in patients with history of disease, monitor for progression
  • Renal impairment: severe GI adverse reactions warrant monitoring of renal function; not recommended in end-stage renal disease
  • CV effects: increased heart rate; PR interval prolongation
  • Caution in patients with hepatic insufficiency

For more information:

Please consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this advertisement.

The Product Monograph is also available by calling us at 1-800-465-4334.

Resources

The latest Ozempic® Product Monograph

Download

Patient Diary

Download

Patient Brochure

Download

Dosing Poster

Download
References and Study Parameters Contact Us Disclaimer & Privacy